Bedi brings significant expertise in strategy, growth, and execution driving technology-enabled innovation across the healthcare industry
“Arjun is an excellent addition to Certara’s board, bringing a powerful combination of technology fluency, growth leadership, and board governance experience,” said Jon Resnick, Chief Executive Officer. “His decades of work with many of the world’s leading pharmaceutical and biotech organizations will be invaluable in supporting greater industry adoption of biosimulation to help speed innovative new medicines to patients.”
“Certara is uniquely positioned at the intersection of biosimulation, AI, and drug development. I’ve seen firsthand how AI-enhanced biosimulation technology can unlock greater certainty in drug development assets while enhancing their commercial performance and patient impact,” said Arjun Bedi. “I'm excited to join the board as Certara is poised for accelerated growth."
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Certara contact:
Sheila Rocchio
[email protected]
Media contact:
Alyssa Horowitz
[email protected]
Certara is transforming drug discovery and development for good
We transform drug development for the benefit of humans. Our commitment is to empower innovators, researchers, and regulatory experts with software and service solutions tailored exactly to meet their needs, fostering success across the entire drug development lifecycle.
